Creso makes European market debut with commercial launch of first animal product
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Creso Pharma (ASX:CPH) has clinched a major milestone with the commercial launch of its first animal health product in Switzerland and Lichtenstein.
CPH has launched its anibidiol® product in partnership with Virbac (EPA:VIRP), a global pharmaceutical animal health company with a considerable presence in over 100 countries.
This move is CPH’s debut into the European market, with many more products expected to follow.
This Swiss approved hemp product is a natural complementary feed for companion animals, containing a standardised amount of hemp extract with cannabidiol (CBD), the non-psychoactive substance of the hemp plant, and is THC free – the first of its kind.
Importantly, anibidiol® is now available to Swiss veterinarians through CPH and Virbac’s partnership.
Anibidiol® promotes the well-being of the companion animal in question by supporting its immunity and natural defence system, also contributing to the pet’s balanced behaviour.
The product contains natural full plant hemp extract, as well as hemp seed oil. This proprietary combination of CBD, the fatty acids Omega 3, Omega 6 and Omega 9, terpenes, flavonoids, and other active herbal ingredients, have a complex interaction which enhances their overall health-promoting effect.
The anibidiol® product range addresses a need for natural, non-pharmaceutical therapeutic approaches which are well-tolerated by animals. The CBD it contains does not cause GI and dependency side-effects, and has an excellent safety and tolerability profile.
There’s also a clearly receptive demographic for a product of this kind, considering that 41 percent of pet owners have considered or tried various alternative therapies, including nutritional supplements (29%) and herbal remedies (7%).
However, the size of the market share CPH can secure remains to be seen at this stage, so if considering this stock for your portfolio do your own research and seek professional financial advice.
The individually packed portions contain a granulate formulation, which is mixed once a day with the pet’s food.
In order to guarantee professional advice, anibidiol® is marketed in Switzerland exclusively by Virbac and only through veterinary practices.
Anibidiol® was developed by CPH, produced in Switzerland by CPH’s partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco), and is marketed exclusively in Switzerland by Virbac (Switzerland) AG, Glattbrugg ZH.
Headquartered in Zurich-Glattbrugg, Virbac has an extensive market reach, with more than 4,800 employees and sales subsidiaries across 31 countries. Its wide range of vaccines and medicines are used in the prevention and treatment of the main pathologies for companion and food-producing animals.
With a turnover of €872 million in 2016, Virbac is the seventh largest pharmaceutical veterinary company worldwide, making it a highly salient partner for CPH as it follows through on its animal health strategy in Europe and beyond.
CPH is entering a fertile market with razor-sharp timing. The recession‐resistant global animal health market is estimated to be US$30 billion (A$39.4 billion), and is projected to continue growing at a rapid rate.
CPH CEO and co-founder, Dr. Miri Halperin Wernli, said: “We are very excited to launch anibidiol® in Switzerland and thrilled to be working in partnership with Virbac, such a well-established global company in the animal health field.”
“This is the first introduction of our hemp-based complementary feed products for companion animals in the veterinary market,” she said. “It is a particularly significant launch for us as it is Creso’s first product launch in Europe and we intend to follow it with many more.”
“We look forward to working with Virbac to successfully promote, market and launch further quality hemp-based animal health products.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
